Background/aim: Total-body irradiation and/or administration of chemotherapy drugs in bone marrow transplantation induce cytokines that can suppress engraftment. Fanconi Anemia (FA) patients have a hyperactive responsiveness to the inhibitory cytokine, transforming growth factor-beta (TGF-β). Small molecule radiation mitigator drugs, JP4-039 and MMS350, were evaluated for suppression of irradiation or drug-induced TGF-β.
Materials And Methods: In vivo induction of TGF-β by total-body ionizing irradiation (TBI), L-phenylalanine mustard (L-PAM), busulfan or fludarabine, was quantified. In parallel, mitigator drug amelioration of TGF-β induction in FA D2 (FANCD2) mouse bone marrow, was studied in vitro. Tissue culture medium, cell lysates, and mouse plasma were analyzed for TGF-β levels.
Results: Induction of TGF-β levels in FANCD2 and FANCD2 mice and in mouse bone marrow were modulated by both JP4-039 and MMS350.
Conclusion: Bone marrow transplantation in FA recipients may benefit from administration of small molecule agents that suppress TGF-β induction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411740 | PMC |
http://dx.doi.org/10.21873/invivo.11040 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!